Top 10 next-generation imaging stories in 2022
As the year comes to a close, we revisit some of this year’s top content on next-generation imaging.
There’s been an abundance of news surrounding imaging agents in the urologic space over the past year. In light of all the progress that’s been made, Urology Times® is counting down the top pieces of content on next-generation imaging in 2022.
10. Dr. Morris on how PSMA-PET imaging has “exploded” in the past year
“We all recognize it’s better than conventional imaging in terms of finding metastatic lesions and with that, it enables us to grow our potential patient basefor targeted therapies,” David Morris, MD. Watch now.
9. Dr. Marks on how PSMA imaging is “opening doors” in prostate cancer
Leonard S. Marks, MD, explained how the Journal of Urology review on prostate-specific antigen membrane imaging for prostate cancer will affect urologists and patients alike. Watch now.
8. Novel PSMA-targeted therapy highly active in mCRPC
Over 90% of patients with metastatic castration-resistant prostate cancer (mCRPC) who received the PSMA-targeted therapy 225Ac-PSMA-617 had a 50% or greater reduction in their PSA level, according to study findings published online in The Journal of Nuclear Medicine. Read more.
7. FDA authorizes trial of novel PSMA-PET imaging diagnostic in prostate cancer
The FDA authorized the launch of the phase 1/2 COBRA trial exploring the novel PSMA-PET imaging agent 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy. Read more.
6. Yale-led study seeks to understand how PSMA-PET imaging is touching the lives of patients with prostate cancer
“We now have convincing evidence that these tests help identify more sites of prostate cancer," said Michael Leapman, MD. Read more.
5. FDA approves 177Lu-PSMA-617 for PSMA-positive mCRPC
The FDA approved the targeted radioligand therapy 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto)for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting. Read more.
4. 177Lu-PSMA-617 production, trial enrollment resumes
Novartis announced in a news release that it resumed production of 177Lu-PSMA-617, along with screening and enrollment for all global clinical trials of the targeted radioligand therapy. Read more.
3. Expert explains significance of FDA approval of 177Lu-PSMA-617 for mCRPC
Richard Wahl, MD, discussed the approval of the targeted radioligand therapy 177Lu-PSMA-617for the treatment of patientswith PSMA-positive metastatic castration-resistant prostate cancer and the significance of Lu 177 vipvotide tetraxetan in the prostate cancer treatment paradigm. Read more.
2. Dr. Tagawa recaps breakthroughs with therapeutic radiopharmaceuticals in prostate cancer
Dr. Tagawa discussed the evolution of therapeutic radiopharmaceuticals in prostate cancer, which he presented on at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Read more.
1. NCCN, SNMMI add piflufolastat F18 to guidelines for prostate cancer imaging
The National Comprehensive Cancer Network and the Society of Nuclear Medicine and Molecular Imaging guidelines expanded to include the use of piflufolastat F 18 (Pylarify), along with all approved PSMA-PET imaging agents, for the selection of prostate cancer patients to receive PSMA-targeted radioligand therapy. Read more.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
